17701-61-0

Basic information

• Product Name: BENZYL 3-HYDROXY-2,2-DIMETHYLPROPANOATE
• Synonyms: BENZYL 3-HYDROXY-2,2-DIMETHYLPROPANOATE;Benzyl 3-Hydroxy-2,2-dimethylpropionate
• CAS NO: 17701-61-0
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25
• Mol File: 17701-61-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: BENZYL 3-HYDROXY-2,2-DIMETHYLPROPANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 3-HYDROXY-2,2-DIMETHYLPROPANOATE(17701-61-0)
• EPA Substance Registry System: BENZYL 3-HYDROXY-2,2-DIMETHYLPROPANOATE(17701-61-0)

Safety Data

• Hazardous Substances Data: 17701-61-0(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 4835-90-9 3-Hydroxy-2,2-dimethylpropanoic acid 
• 7285-83-8 2,4,6-tris(benzyloxy)-1,3,5-triazine 
• 21620-60-0 2-methylglyceric acid 
• 1301764-12-4 cesium salt of 2,2-dimethyl-3-hydroxypropionic acid 
• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 

Downstream Products

• 64241-77-6 β-Fluoro-pivalic acid 
• 1955-45-9 pivalolactone 
• 1531585-26-8 benzyl 2-cyclopropyl-2-methylpropanoate 
• 1379614-04-6 3-(benzoyloxy)-2,2-dimethylpropyl benzoate 
• 1379613-69-0 3-(benzyloxy)-2,2-dimethyl-3-oxopropyl thiophene-2-carboxylate 
• 1447942-30-4 benzyl 3,3-difluoro-2,2-dimethylpropanoate 
• 1337544-05-4 benzyl 3-(2-cyano-3-nitrophenoxy)-2,2-dimethylpropanoate 
• 1337544-04-3 benzyl 3-(3-amino-2-cyanophenoxy)-2,2-dimethylpropanoate 
• 661480-83-7 4-(2-benzyloxycarbonyl-2-methylpropoxy)benzaldehyde 
• 464189-13-7 N-(2-cyclohexylcarbamoyl-2-methyl-propoxy)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-2,2-dimethyl-propionamide 
• 464189-17-1 N-cyclohexyl-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-2,2-dimethyl-propionamide 

Relevant articles and documents

Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study

Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.

Biocatalytic Construction of Quaternary Centers by Aldol Addition of 3,3-Disubstituted 2-Oxoacid Derivatives to Aldehydes

The congested nature of quaternary carbons hinders their preparation, most notably when stereocontrol is required. Here we report a biocatalytic method for the creation of quaternary carbon centers with broad substrate scope, leading to different compound classes bearing this structural feature. The key step comprises the aldol addition of 3,3-disubstituted 2-oxoacids to aldehydes catalyzed by metal dependent 3-methyl-2-oxobutanoate hydroxymethyltransferase from E. coli (KPHMT) and variants thereof. The 3,3,3-trisubstituted 2-oxoacids thus produced were converted into 2-oxolactones and 3-hydroxy acids and directly to ulosonic acid derivatives, all bearing gem-dialkyl, gem-cycloalkyl, and spirocyclic quaternary centers. In addition, some of these reactions use a single enantiomer from racemic nucleophiles to afford stereopure quaternary carbons. The notable substrate tolerance and stereocontrol of these enzymes are indicative of their potential for the synthesis of structurally intricate molecules.

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1)

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

O-Benzylation of Carboxylic Acids Using 2,4,6-Tris(benzyloxy)-1,3,5-triazine (TriBOT) under Acidic or Thermal Conditions

Two methods for the synthesis of benzyl esters from carboxylic acids using the O-benzylating reagent 2,4,6-tris(benzyloxy)-1,3,5-triazine (TriBOT) have been developed. The reactions were conducted either in the presence of a catalytic amount of TfOH at room temperature (acidic conditions) or in the absence of TfOH at 180-230 C (thermal conditions). Interestingly, the O-benzylation of hydroxy carboxylic acids under the two conditions afforded different products: The dibenzylated product under acidic conditions and the hydroxy ester under thermal conditions. In addition to these results, other evidence indicated that the former reaction proceeds through an SN1-type mechanism, and the latter by an SN2-type mechanism. Two methods for the O-benzylation of carboxylic acids using TriBOT have been developed under either acidic or thermal conditions. The O-benzylation of hydroxy carboxylic acids afforded the dibenzylated product under acidic conditions and the hydroxy ester under thermal conditions. The former reaction proceeds through an SN1-type mechanism and the latter by an SN2-type mechanism.

Synthesis of the spiroacetal core of the cephalosporolide family of natural products

The synthesis of four possible stereoisomers of the spiroacetal core of the natural products cephalosporolides H and I and penisporolides A and B is described. The key steps involve the use of Sharpless asymmetric dihydroxylation to install the desired stereochemistry of the γ-lactone ring and an oxidative radical cyclisation to form the spiroacetal ring system.

NOVEL COMPOUND AND MEDICAL USE THEREOF

Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)p

MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE

Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs

KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.

PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.